{"id":"poly-ic","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL470172","moleculeType":"Small molecule","molecularWeight":"764.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Poly IC (polyinosinic-polycytidylic acid) mimics viral double-stranded RNA and binds to TLR3 on immune cells, triggering interferon production and activation of natural killer cells and cytotoxic T lymphocytes. This enhances antiviral and antitumor immune responses through pattern recognition receptor activation.","oneSentence":"Poly IC is a synthetic double-stranded RNA analog that activates innate immune responses through toll-like receptor 3 (TLR3) signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:43.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (various malignancies)"},{"name":"Viral infections"}]},"trialDetails":[{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT05098210","phase":"PHASE1","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma","enrollment":25},{"nctId":"NCT04420975","phase":"PHASE1","title":"Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-10-14","conditions":"Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma","enrollment":14},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT06342908","phase":"PHASE1","title":"A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-06-14","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":6},{"nctId":"NCT04266730","phase":"PHASE1","title":"Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02-22","conditions":"Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":6},{"nctId":"NCT06422936","phase":"PHASE2","title":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Highlight Therapeutics","startDate":"2024-05-27","conditions":"Basal Cell Carcinoma","enrollment":60},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT06472661","phase":"EARLY_PHASE1","title":"FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-09-27","conditions":"Advanced Melanoma","enrollment":11},{"nctId":"NCT01720836","phase":"PHASE1, PHASE2","title":"Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Olivera Finn","startDate":"2012-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT03223103","phase":"PHASE1","title":"Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adilia Hormigo","startDate":"2018-03-01","conditions":"Glioblastoma","enrollment":13},{"nctId":"NCT04201873","phase":"PHASE1","title":"Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-01-08","conditions":"Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT03206047","phase":"PHASE1, PHASE2","title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-08","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT05457959","phase":"PHASE1","title":"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":""},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT02834052","phase":"PHASE1, PHASE2","title":"Pembrolizumab + Poly-ICLC in MRP Colon Cancer","status":"COMPLETED","sponsor":"Asha Nayak","startDate":"2018-01-10","conditions":"Metastatic Colon Cancer, Solid Tumor","enrollment":42},{"nctId":"NCT06343077","phase":"PHASE2","title":"Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance","status":"RECRUITING","sponsor":"Ashutosh Kumar Tewari","startDate":"2024-01-16","conditions":"Prostate Cancer Patients on Active Surveillance","enrollment":114},{"nctId":"NCT03131765","phase":"PHASE1","title":"Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2017-04-20","conditions":"Cancer","enrollment":31},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT04777708","phase":"EARLY_PHASE1","title":"BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-10-13","conditions":"Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma","enrollment":1},{"nctId":"NCT02166905","phase":"PHASE1, PHASE2","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2014-10-10","conditions":"Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma","enrollment":40},{"nctId":"NCT01976585","phase":"PHASE1, PHASE2","title":"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy","status":"COMPLETED","sponsor":"Joshua Brody","startDate":"2014-01-03","conditions":"Low-Grade B-cell Lymphoma","enrollment":21},{"nctId":"NCT03262103","phase":"PHASE1","title":"Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer","status":"COMPLETED","sponsor":"Ashutosh Kumar Tewari","startDate":"2017-06-16","conditions":"Prostate Cancer","enrollment":13},{"nctId":"NCT01834248","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2013-07-30","conditions":"Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":9},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT02129075","phase":"PHASE2","title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-09","conditions":"Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary","enrollment":60},{"nctId":"NCT02090374","phase":"NA","title":"Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-03","conditions":"Allergic Rhinitis, Asthma, Latent Tuberculosis","enrollment":93},{"nctId":"NCT00694551","phase":"NA","title":"PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2008-12-02","conditions":"Prostate Cancer","enrollment":29},{"nctId":"NCT03392545","phase":"PHASE1","title":"Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2018-04-01","conditions":"High Grade Glioma, Glioblastoma, Glioma of Brainstem","enrollment":30},{"nctId":"NCT03732547","phase":"PHASE2","title":"Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-22","conditions":"Carcinoma, Hepatocellular","enrollment":60},{"nctId":"NCT03338556","phase":"PHASE2","title":"A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16","status":"COMPLETED","sponsor":"Prep Biopharm Limited","startDate":"2016-04-06","conditions":"Viral Upper Respiratory Tract Infection","enrollment":102},{"nctId":"NCT00986609","phase":"EARLY_PHASE1","title":"MUC1 Vaccine for Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Joseph Baar, MD, PhD","startDate":"2009-08-19","conditions":"Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer","enrollment":29},{"nctId":"NCT01842139","phase":"PHASE1","title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-12-05","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":7},{"nctId":"NCT01079741","phase":"PHASE1, PHASE2","title":"Safety Study of Adjuvant Vaccine to Treat Melanoma Patients","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2010-09","conditions":"Melanoma","enrollment":34},{"nctId":"NCT03198676","phase":"PHASE1","title":"A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production","status":"COMPLETED","sponsor":"Prep Biopharm Limited","startDate":"2017-05-08","conditions":"Upper Respiratory Tract Infections","enrollment":20},{"nctId":"NCT00374049","phase":"PHASE1","title":"MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Olivera Finn","startDate":"2006-06","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT02532413","phase":"PHASE4","title":"Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-07","conditions":"Chronic Hepatitis B","enrollment":180},{"nctId":"NCT01299662","phase":"PHASE1","title":"Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2011-06","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT00094003","phase":"PHASE1","title":"Study of NS-9 in Patients With Liver Metastases","status":"COMPLETED","sponsor":"NS Pharma, Inc.","startDate":"2002-09","conditions":"Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyinosinic-polycytidylic acid injection"],"phase":"marketed","status":"active","brandName":"Poly IC","genericName":"Poly IC","companyName":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","companyId":"union-hospital-tongji-medical-college-huazhong-university-of-science-and-technol","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Poly IC is a synthetic double-stranded RNA analog that activates innate immune responses through toll-like receptor 3 (TLR3) signaling. Used for Cancer immunotherapy (various malignancies), Viral infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}